Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm

Summary

This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.

Eligibility

Inclusion Criteria:

* Presence or suspicion of intracranial neoplasm in two populations:

  * Population 1: Participants after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on MRI.
  * Three sub-populations will be considered:

    * Recurrent metastatic lesions.
    * Recurrent high-grade gliomas (Grades 3 and 4).
    * Recurrent low-grade gliomas (Grade 2).
  * Population 2: Participants prior to primary treatment with planned biopsy or surgical resection.
* Age \> 3 years.

Participants in other clinical trials will be eligible for this study including patients undergoing surgery guided by 5-aminolevulinic acid.

Exclusion Criteria:

* Participants with known incompatibility to PET or Computerized tomography (CT)/magnetic resonance imaging (MRI) scans.
* Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.

  * Sedation or anesthesia can be used for participants who cannot tolerate the exam.

Conditions2

Locations1 site

Browse More Trials